Abstract 122P
Background
Renal Cell Carcinoma (RCC) subtypes are identified based on their histological features, which are crucial for determining prognosis and treatment options. Nevertheless, the histological classification of RCC often faces challenges in predicting treatment responses and outcomes because of its heterogeneity. To address this issue, multi-omics approaches have revealed a new molecular subtype by analyzing the genome and expression profiles of various tumor types. In this study, we performed an extensive profiling of RCC.
Methods
A total of 113 paired tumor and adjacent non-tumor tissues, as well as PBMC samples, were collected from Korean RCC patients. This study was approved by the Institutional Review Board of the Severance Hospital, Yonsei University Health System (IRB No. 4-2018-0986) and Chonnam National University Hospital (IRB No. NUHH-2018-167). All patients provided consent for their samples to be used for research purposes. These samples underwent Whole Exome Sequencing (WES), RNA sequencing (WTS), Proteomics, and Phospho-proteomics analyses.
Results
The multi-omics analysis of 113 clear cell renal cell carcinoma (ccRCC) patients reveals distinct genomic, proteomic, and clinical characteristics separating RCC tumors from normal tissues. The study identifies four RCC subtypes (C1-4) with unique molecular profiles and prognostic implications. C1-3 are mostly ccRCC, while C4 includes non-clear cell RCC (nccRCC) or other cancer types. C3 shows the poorest prognosis, whereas C1 has the best. C1 also exhibits a strong adaptive immune response and angiogenesis, correlating with favorable post-surgery outcomes. C2 is enriched in DNA repair pathways with specific gene alterations, while C3 is linked to an inflammatory response and resistance to certain treatments.
Conclusions
This study employs a large-scale multi-omics approach to RCC, offering insights into its biological foundations and supporting rational treatment selection by linking multi-omics-derived phenotypes to clinical outcomes in ccRCC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
National Cancer Center Korea.
Disclosure
S. Park: Financial Interests, Institutional, Sponsor/Funding: National Cancer Center, Korea. All other authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives
Presenter: Asma Al- Bahri
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract